Immunome Inc.
IMNMNext catalyst
AL102
adults with desmoid tumors
Get an email about IMNM's next catalysts
Track Immunome (IMNM) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
No other upcoming event in our data.
1 upcoming, 2 past
FDA PDUFA Date varegacestat
For adults with desmoid tumors. NDA filing. Extracted from SEC filing: EX-99.1
SourceUpcoming FDA decisions
Market Overview
Stock performance and key metrics
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
AL102 | Phase 3 | Desmoid | - | - |
Frequently asked questions
What is in Immunome Inc.'s drug pipeline?β
CatalystAlert tracks 1 drug candidate in Immunome Inc.'s (IMNM) pipeline across Phase 3. Its lead program is AL102 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Immunome Inc.'s next FDA catalyst?β
Immunome Inc.'s (IMNM) next tracked catalyst is a PDUFA date expected Apr 28, 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track IMNM biotech catalysts?β
Add IMNM to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Immunome Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page β sourced from ClinicalTrials.gov, FDA and SEC filings.
